Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.
IPO Year:
Exchange: AMEX
Website: protalix.com
| Date | Price Target | Rating | Analyst |
|---|
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4/A - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2024, and provided a business and clinical update. "We are pleased to report that all eight cohorts of our phase I first-in-human study of PRX-115, our recombinant uricase candidate being developed for the treatment of uncontrolled gout, are now complete,
Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel, Nov. 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended September 30, 2024 and provide a business and clinical update on November 14, 2024. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2024, and provided a business update. "In the second quarter, Protalix has made meaningful progress on our early-stage pipeline," said Dror Bashan, Protalix's President and Chief Executive Officer. "Results from the first seven cohorts of the phase I clinical
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, Aug. 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended June 30, 2024 and provide a business and clinical update on August 14, 2024. Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 10, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update. "We are pleased to announce that initial top-line results from the first seven cohorts of the first-in-human phase I clinical trial of our recombinant uricase candidate, PRX-115, are encouraging, enabling us t
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, May 3, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024. Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call De
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2023, and provided a business update. "2023 was a significant year for Protalix, as we received regulatory approvals of Elfabrio for the treatment of adult patients with Fabry disease and advanced our growing pipeline," said Dror Bashan, Protalix'
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2023 and provide a business update on Thursday, March 14, 2024. Management will host a conference call with investors to discuss the financial results and provide a business update. Conference Call Details:Date:
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 7, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the second quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments. "2023 has been a transformational year for Protalix thus far," said Dror Bashan, Protalix's President and Chief Executive Officer. "We are very proud to have re
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, July 31, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the second quarter ended June 30, 2023 and provide a business update on Monday, August 7, 2023. Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments at 8:30 a.m
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
S-8 - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
ARS - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
DEFA14A - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
HC Wainwright & Co. reiterated coverage of Protalix BioTherapeutics with a rating of Buy and set a new price target of $7.00 from $11.00 previously
CARMIEL, Israel, Dec. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders. December 23, 2024 Dear Protalix Stockholders, As we conclude 2024, I am filled with a sense of accomplishment as well as excitement for the year ahead. This past year, Protalix has achieved significant milestones that position our company for long-term growth. The success
Application to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every four weeks in adult patients with Fabry disease in European UnionPARMA, Italy and CARMIEL Israel, Dec. 9, 2024 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that the European Medicines Agency (
Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2024, and provided a business and clinical update. "We are pleased to report that all eight cohorts of our phase I first-in-human study of PRX-115, our recombinant uricase candidate being developed for the treatment of uncontrolled gout, are now complete,
Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel, Nov. 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended September 30, 2024 and provide a business and clinical update on November 14, 2024. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details
CARMIEL, Israel, Oct. 25, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that data from the phase I clinical trial of PRX-115, the Company's recombinant PEGylated uricase product candidate in development for the treatment of uncontrolled gout, will be presented in a late-breaking poster at the American College of Rheumatology (ACR) Convergence 2024, being held November 14-19, 2024 at the Walter E. Washington Convention Center in Washington, D.C.
CARMIEL, Israel, Sept. 4, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference which is being held on September 9–11, 2024 at the Lotte New York Palace Hotel, New York City, NY. Mr. Bashan will present on Wednesday, September 11, at 12:30 p.m. Eastern Daylight Time (EDT) in the Holmes II Room, Fourth floo
Company is debt-free with no outstanding notes Balance sheet provides sufficient runway for ongoing operations CARMIEL, Israel, Sept. 3, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it has repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Promissory Notes. The repayment of the convertible notes at maturity was financed entirely with available cash. "Repayment of our convertibl
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2024, and provided a business update. "In the second quarter, Protalix has made meaningful progress on our early-stage pipeline," said Dror Bashan, Protalix's President and Chief Executive Officer. "Results from the first seven cohorts of the phase I clinical
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, Aug. 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended June 30, 2024 and provide a business and clinical update on August 14, 2024. Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call
Event will take place on Wednesday, June 26, 2024 in New York CARMIEL, Israel, June 13, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will host an in-person investor day at the Lotte Palace New York Hotel in New York on Wednesday, June 26, 2024 at 8:30 a.m. Eastern Daylight Time (EDT). The investor day will feature presentations by the following key opinion leaders: Aleš Linhart, DSc, FESC (Charles University, Prague), who will discuss the treat
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur
Appointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel, Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that the Company's Board of Directors has appointed Eliot Richard Forster, Ph.D. to serve on the Board of Directors as its Chairman, effective as of September 14, 2023. In
CARMIEL, Israel, June 30, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), announced today that the Company's Board of Directors has appointed Shmuel "Muli" Ben Zvi, Ph.D. to serve on the Company's Board of Directors. In addition to Dr. Ben Zvi's appointment as an independent director, he was also appointed to serve on the Company's Audit Committee and Compensation Committee. "We are excited to have Muli join our Board of Directors," commented Zeev Bronfeld, Chairman of Protalix's Board of Directors. "He brings extensive financial and economic knowle
CARMIEL, Israel, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its shareholders and the investment community. Dear Protalix shareholders, As we look forward to 2021 with great anticipation, I want to take a moment to reflect on our transformational accomplishments this past year, which has been unlike any we could have imagined. Together
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
SC 13G - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)